Al Benson, MD
Medical Oncology · Chicago, ILNPI 1891761532
Payments from drug & device makers
Across 268 payments — averaging $5857.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$588K
- Bristol Myers Squibb$532K
- AbbVie$95K
- Amgen$93K
- GSK$51K
- Daiichi Sankyo Inc.$44K
- plus $166K from 31 others
Across 1 payment — averaging $670.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$670
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 107 | $588,364 |
| Bristol Myers Squibb | 3 | $531,756 |
| AbbVie | 10 | $95,370 |
| Amgen | 12 | $92,509 |
| GSK | 16 | $51,496 |
| Daiichi Sankyo Inc. | 2 | $43,822 |
| Boehringer Ingelheim | 1 | $39,869 |
| E.r. Squibb & Sons, L.L.C. | 26 | $14,782 |
| Pfizer | 4 | $13,304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $12,676 |
| Incyte Corporation | 11 | $9,747 |
| Array Biopharma Inc | 4 | $9,254 |
| Terumo Medical Corporation | 7 | $8,200 |
| Taiho Oncology, Inc. | 8 | $7,664 |
| Boehringer Ingelheim International GmbH | 2 | $6,500 |
| Eisai Inc. | 3 | $5,533 |
| AVEO Pharmaceuticals, Inc. | 1 | $5,000 |
| Lexicon Pharmaceuticals, Inc. | 5 | $4,991 |
| Sanofi | 2 | $3,855 |
| Corcept Therapeutics | 3 | $3,119 |
| Delcath Systems | 1 | $3,000 |
| Jazz Pharmaceuticals Inc. | 1 | $2,450 |
| Astrazeneca UK Limited | 1 | $2,226 |
| Gilead(2 entities) | 2 | $2,209 |
| Boston Scientific | 2 | $2,118 |
| Advanced Accelerator Applications | 3 | $1,935 |
| Bayer | 1 | $1,750 |
| Mirati Therapeutics, Inc. | 3 | $1,400 |
| Seagen Inc. | 1 | $1,380 |
| Samsung Bioepis Co., Ltd. | 2 | $1,000 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 5 | $853 |
| Shionogi Inc | 3 | $816 |
| Genentech USA, Inc. | 3 | $419 |
| AstraZeneca | 3 | $134 |
| Iovance Biotherapeutics, Inc. | 1 | $130 |
| BTG International Inc. | 1 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $22 |
How this compares
$1,569,682 in reported general payments places this provider in the 90th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Chicago
- Andrzej JakubowiakChicago$42M
- Alexander PearsonChicago$9.3M
- Jyoti PatelChicago$7.5M
- Devalingam MahalingamChicago$7.1M
- Ardaman ShergillChicago$4.9M
- Sunandana ChandraChicago$4.6M
- William GradisharChicago$3.3M
- Manali BhaveChicago$3.3M
- Eugene AhnChicago$2.8M
- Nisha MohindraChicago$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.